205 related articles for article (PubMed ID: 10328593)
1. Monoclonal antibodies as potentiators of radiotherapy and chemotherapy in the management of head and neck cancer.
Wheeler RH; Spencer S; Buchsbaum D; Robert F
Curr Opin Oncol; 1999 May; 11(3):187-90. PubMed ID: 10328593
[TBL] [Abstract][Full Text] [Related]
2. Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck.
Bonner JA; Harari PM; Giralt J; Azarnia N; Shin DM; Cohen RB; Jones CU; Sur R; Raben D; Jassem J; Ove R; Kies MS; Baselga J; Youssoufian H; Amellal N; Rowinsky EK; Ang KK
N Engl J Med; 2006 Feb; 354(6):567-78. PubMed ID: 16467544
[TBL] [Abstract][Full Text] [Related]
3. Review of current treatment practices for carcinoma of the head and neck.
Modi BJ; Knab B; Feldman LE; Mundt AJ; Yao M; Pytynia KB; Epstein J
Expert Opin Pharmacother; 2005 Jun; 6(7):1143-55. PubMed ID: 15957968
[TBL] [Abstract][Full Text] [Related]
4. Cetuximab and radiotherapy for head and neck cancer.
Posner MR; Wirth LJ
N Engl J Med; 2006 Feb; 354(6):634-6. PubMed ID: 16467552
[No Abstract] [Full Text] [Related]
5. Management of radiation dermatitis in patients receiving cetuximab and radiotherapy for locally advanced squamous cell carcinoma of the head and neck: proposals for a revised grading system and consensus management guidelines.
Bernier J; Russi EG; Homey B; Merlano MC; MesÃa R; Peyrade F; Budach W
Ann Oncol; 2011 Oct; 22(10):2191-200. PubMed ID: 21606209
[TBL] [Abstract][Full Text] [Related]
6. IMC-C225, an anti-epidermal growth factor receptor monoclonal antibody, for treatment of head and neck cancer.
Herbst RS; Kim ES; Harari PM
Expert Opin Biol Ther; 2001 Jul; 1(4):719-32. PubMed ID: 11727507
[TBL] [Abstract][Full Text] [Related]
7. Hypofractionated radiotherapy plus cetuximab in locally advanced head and neck cancer.
Teoh DC; Rodger S; Say J; Hartley A
Clin Oncol (R Coll Radiol); 2008 Nov; 20(9):717. PubMed ID: 18757187
[No Abstract] [Full Text] [Related]
8. Consensus guidelines for the management of radiation dermatitis and coexisting acne-like rash in patients receiving radiotherapy plus EGFR inhibitors for the treatment of squamous cell carcinoma of the head and neck.
Bernier J; Bonner J; Vermorken JB; Bensadoun RJ; Dummer R; Giralt J; Kornek G; Hartley A; Mesia R; Robert C; Segaert S; Ang KK
Ann Oncol; 2008 Jan; 19(1):142-9. PubMed ID: 17785763
[TBL] [Abstract][Full Text] [Related]
9. Phase I trial of dacomitinib, a pan-human epidermal growth factor receptor (HER) inhibitor, with concurrent radiotherapy and cisplatin in patients with locoregionally advanced squamous cell carcinoma of the head and neck (XDC-001).
Prawira A; Brana-Garcia I; Spreafico A; Hope A; Waldron J; Razak AR; Chen EX; Jang R; O'Sullivan B; Giuliani M; Bayley A; Cho J; Wang L; Perez-Ordonez B; Weinreb I; Siu LL; Hansen AR
Invest New Drugs; 2016 Oct; 34(5):575-83. PubMed ID: 27289242
[TBL] [Abstract][Full Text] [Related]
10. Epidermal Growth Factor Receptor Inhibition in Squamous Cell Carcinoma of the Head and Neck.
Machiels JP; Schmitz S
Hematol Oncol Clin North Am; 2015 Dec; 29(6):1011-32. PubMed ID: 26568545
[TBL] [Abstract][Full Text] [Related]
11. Cetuximab plus radiotherapy for head and neck cancer.
Armstrong JG
N Engl J Med; 2006 May; 354(20):2187; author reply 2187. PubMed ID: 16710907
[No Abstract] [Full Text] [Related]
12. Postoperative radiotherapy with simultaneous chemotherapy in high-risk squamous cell carcinoma of the head and neck: a novel standard that opens new questions.
Giralt J; Bernier J
Clin Transl Oncol; 2005 Jun; 7(5):181-2. PubMed ID: 15960928
[No Abstract] [Full Text] [Related]
13. Concurrent chemoradiotherapy for locally advanced, nonmetastatic, squamous carcinoma of the head and neck: consensus, controversy, and conundrum.
Brizel DM; Esclamado R
J Clin Oncol; 2006 Jun; 24(17):2612-7. PubMed ID: 16763273
[TBL] [Abstract][Full Text] [Related]
14. Cetuximab combined with radiotherapy: an alternative to chemoradiotherapy for patients with locally advanced squamous cell carcinomas of the head and neck?
Bernier J; Schneider D
Eur J Cancer; 2007 Jan; 43(1):35-45. PubMed ID: 17098420
[TBL] [Abstract][Full Text] [Related]
15. Immune biomarkers of anti-EGFR monoclonal antibody therapy.
Trivedi S; Concha-Benavente F; Srivastava RM; Jie HB; Gibson SP; Schmitt NC; Ferris RL
Ann Oncol; 2015 Jan; 26(1):40-47. PubMed ID: 24997207
[TBL] [Abstract][Full Text] [Related]
16. Treatment of advanced head and neck cancer with cetuximab.
Merlano M; Garrone O
Int J Biol Markers; 2007; 22(1 Suppl 4):S71-6. PubMed ID: 17520584
[TBL] [Abstract][Full Text] [Related]
17. Cetuximab: its use in combination with radiation therapy and chemo-therapy in the multimodality treatment of head and neck cancer.
Wagner TD; Yang GY
Recent Pat Anticancer Drug Discov; 2008 Jun; 3(2):76-83. PubMed ID: 18537749
[TBL] [Abstract][Full Text] [Related]
18. Cetuximab plus radiotherapy for head and neck cancer.
Hartig F; Pechlaner C
N Engl J Med; 2006 May; 354(20):2187; author reply 2187. PubMed ID: 16710909
[No Abstract] [Full Text] [Related]
19. Clinical trials, referral resource. Treatment of advanced or recurrent squamous cell carcinoma of the head and neck.
Conley BA; Gore-Langton RE; Cheson BD
Oncology (Williston Park); 2000 Apr; 14(4):553-4, 559, 561. PubMed ID: 10826315
[No Abstract] [Full Text] [Related]
20. More on cetuximab in head and neck cancer.
Mell LK; Weichselbaum RR
N Engl J Med; 2007 Nov; 357(21):2201-2; author reply 2202-3. PubMed ID: 18032774
[No Abstract] [Full Text] [Related]
[Next] [New Search]
